secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2022-09-13T23:59:59+00:00
Accession:  0001493152-22-025724
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences appoints Robert Dickey IV as interim CFO effective Sept 9, 2022
--------------------------------------------------------------------------------

- Robert Dickey IV, age 66, appointed as interim CFO effective September 9, 2022.
- Mr. Dickey is Managing Director at Foresite Advisors, providing finance support for life science companies.
- Previously served as CFO of Motif Bio Plc (2017-2018) and Tyme Technologies (2015-2017).
- He holds an MBA from Wharton and a BA from Princeton.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315222025724/0001493152-22-025724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315222025724/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-025724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer